Sanofi (SNY)
| Market Cap | 136.42B |
| Revenue (ttm) | 45.85B |
| Net Income (ttm) | 5.76B |
| Shares Out | 1.25B |
| EPS (ttm) | 4.60 |
| PE Ratio | 23.70 |
| Forward PE | 12.86 |
| Dividend | $2.20 (4.04%) |
| Ex-Dividend Date | May 9, 2024 |
| Volume | 1,390,497 |
| Open | 54.03 |
| Previous Close | 54.13 |
| Day's Range | 53.93 - 54.51 |
| 52-Week Range | 45.22 - 58.97 |
| Beta | 0.46 |
| Analysts | Strong Buy |
| Price Target | 60.00 (+10.17%) |
| Earnings Date | Jan 30, 2025 |
About SNY
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company provides immunology and inflammation, rare diseases, neurology, oncology, and other medicines and vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria, tetanus, pertussis, polio, Hib, and hepatitis B; inf... [Read more]
Financial Performance
In 2024, Sanofi's revenue was 44.29 billion, an increase of 7.73% compared to the previous year's 41.11 billion. Earnings were 5.56 billion, an increase of 2.96%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to one analyst, the rating for SNY stock is "Strong Buy" and the 12-month stock price forecast is $60.0.
News
Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug...
Sanofi: OpenAI's Research Agents Could Lead To Explosive Growth
Sanofi's deep partnership with OpenAI could be a huge differentiating factor as OpenAI's agentic models grow in capabilities. OpenAI's "Deep Research" tool is already incredibly promising for Sanofi i...
Press Release: Sanofi and CD&R sign Opella share purchase agreement
Sanofi and CD&R sign Opella share purchase agreement Paris, February 19, 2025 . Following completion of the required social and corporate procedures, Sanofi and CD&R announce today they have signed th...
Press Release: Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report
Filing of the 2024 U.S. Form 20-F and French “Document d'Enregistrement Universel” containing the Annual Financial Report Paris, February 13, 2025. Sanofi announces today the filing of its Form 20-F w...
Press Release: Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study
Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study Independent interim analysis of the E.mbrace phase 3 study finds that the vaccine candidate didn't demonstrate sufficient ef...
Healthcare company Sanofi announces share buyback of up to 2 billion euros
French healthcare company Sanofi announced on Friday a share buyback plan worth up to 2 billion euros ($2.1 billion), which would be done between now and the end of December.
Press Release: Execution of a share buyback agreement for up to €2 billion
Execution of a share buyback agreement for up to €2 billion Paris, February 7, 2025. On January 30, 2025, Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, prefe...
MITEM PHARMA Continues Its Mission to Protect the Interests of Patients Suffering From Rare and Lethal Diseases by Acquiring the FLISINT® Speciality from SANOFI
MASSY, France--(BUSINESS WIRE)--MITEM PHARMA, a French-based pharmaceutical company dedicated to Drugs of Major Therapeutic Interest (DMTI), is pleased to announce that it has acquired the rights to F...
Agreement Between L'Oréal and Sanofi for the Repurchase by Sanofi of 2.3% of Its Own Shares Held by L'Oréal
AGREEMENT BETWEEN L'ORÉAL AND SANOFI FOR THE REPURCHASE BY SANOFI OF 2.3% OF ITS OWN SHARES HELD BY L'ORÉAL
Press Release: Sanofi announces buy back of shares from L'Oréal
Sanofi announces buy back of shares from L'Oréal Paris, February 3, 2025. Sanofi today announces the acquisition of 2.3% of its shares from long-standing shareholder L'Oréal.
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant
Sanofi (SNY) Q4 2024 Earnings Call Transcript
Sanofi (NASDAQ:SNY) Q4 2024 Results Conference Call January 30, 2025 9:00 AM ET Company Participants Thomas Larsen - Head of Investor Relations Paul Hudson - Chief Executive Officer Francois Roger - ...
Sanofi CEO Paul Hudson on RFK Jr.'s vaccine stance
Sanofi CEO Paul Hudson discusses the company's quarterly earnings results and his thoughts on the confirmation hearing of RFK Jr.
Sanofi CEO Paul Hudson on Q4 results: We've set ourselves up very well for 2025
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, the company's dividend and buyback decision, his thoughts on the confirmatio...
Sanofi meets estimates for fourth-quarter profit, plans 5 billion euros in buybacks
French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts' estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it se...
'The next battleground': Sanofi exploring opportunities in second generation obesity drugs
Paul Hudson, CEO of Sanofi, says his firm is exploring the second generation of obesity drugs, noting that solutions for sustained weight loss were "the next battleground."
Press Release: Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
Sarclisa approved in the EU as the first anti-CD38 therapy in combination with standard-of-care VRd to treat transplant-ineligible newly diagnosed multiple myeloma
Press Release: Opella reaches study milestone for Cialis
Opella reaches study milestone for Cialis Paris, January 21, 2025. Opella, Sanofi's Consumer Healthcare business, announced that the US Food and Drug Administration (FDA) has lifted a clinical hold on...
Top 4 Immunology Stocks Poised For Growth In 2025
This article will reveal an in-depth analysis of drugs being developed to combat immunological disorders. Big Pharma is keenly interested in the global immunology drugs market, which is anticipated to...
Sanofi (SYN) CEO Paul Hudson Hosts 43rd Annual J.P. Morgan Healthcare (Transcript)
Sanofi (SYN) 43rd Annual J.P. Morgan Healthcare January 14, 2025 12:45 PM ET Company Participants Paul Hudson - Chief Executive Officer Francois-Xavier Roger - Chief Financial Officer Houman Ashrafian...
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...
Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi
ALAMEDA, Calif.--(BUSINESS WIRE)-- #CRISPR--Scribe Therapeutics achieves milestone for in vivo program in collaboration with Sanofi.
Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Sanofi: Underappreciated Powerhouse Primed For Long-Term Growth (Rating Upgrade)
Sanofi's Q3 revenue grew by 12.3% to €13.438 billion, driven by products like Dupixent and influenza vaccines. Dupixent remains a top growth driver, with potential peak sales exceeding $20 billion, in...
Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpo...